Pharmaceutical giant Merck (NYSE: MRK) delivered outstanding second-quarter results in July, largely driven by its mainstay cancer blockbuster, Keytruda. The company reported 28% year-over-year total revenue growth and continues to develop Keytruda for new cancer indications.

Under the radar, however, Keytruda returned some bad news in three separate late-stage clinical trials this summer. What does this mean for Merck's oncology franchise? 

Superstar cancer drug Keytruda is currently approved for at least 14 different types of cancers and counting. It has shown itself to be a versatile therapy that is considered a standard-of-care treatment for many cancer indications, either as a stand-alone treatment or in combination with other therapies.

Continue reading

Source Fool.com